thalidomide has been researched along with Ulcer in 38 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to determine the clinical efficacy of apremilast for oral ulcers (OUs), extra-oral manifestations, and overall disease activity in patients with Behçet's disease (BD)." | 9.22 | Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis. ( Hirahara, L; Horita, N; Iizuka, Y; Kirino, Y; Mizuki, N; Nakajima, H; Namkoong, HO; Soejima, Y; Takase-Minegishi, K; Takeno, M; Takeuchi, M; Yoshimi, R, 2022) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 9.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "Though thalidomide in a dosage of 100 mg/day is the standard treatment for recurrent oral and genital ulcers (OGU), its toxicity would be less important with lower dosage, while its efficacy would be identical." | 9.09 | [Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients]. ( Berthier, S; de Wazières, B; Dupond, JL; Gil, H; Magy, N; Vuitton, DA, 1999) |
| "Thalidomide appears to be highly effective for oropharyngeal apthous ulcers in HIV-infected patients." | 9.08 | A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. ( Alexander, LN; Wilcox, CM, 1997) |
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 9.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 9.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 9.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "To examine the efficacy, dose, and safety profile, including neurophysiological testing of thalidomide used in 59 patients (including 23 with Behçet's disease) to treat severe oral or genital ulceration (OGU)." | 7.69 | Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. ( Gardner-Medwin, JM; Powell, RJ; Smith, NJ, 1994) |
| "This study aimed to determine the clinical efficacy of apremilast for oral ulcers (OUs), extra-oral manifestations, and overall disease activity in patients with Behçet's disease (BD)." | 5.22 | Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis. ( Hirahara, L; Horita, N; Iizuka, Y; Kirino, Y; Mizuki, N; Nakajima, H; Namkoong, HO; Soejima, Y; Takase-Minegishi, K; Takeno, M; Takeuchi, M; Yoshimi, R, 2022) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 5.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "Though thalidomide in a dosage of 100 mg/day is the standard treatment for recurrent oral and genital ulcers (OGU), its toxicity would be less important with lower dosage, while its efficacy would be identical." | 5.09 | [Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients]. ( Berthier, S; de Wazières, B; Dupond, JL; Gil, H; Magy, N; Vuitton, DA, 1999) |
| "Thalidomide appears to be highly effective for oropharyngeal apthous ulcers in HIV-infected patients." | 5.08 | A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. ( Alexander, LN; Wilcox, CM, 1997) |
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 5.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 5.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 5.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "To examine the efficacy, dose, and safety profile, including neurophysiological testing of thalidomide used in 59 patients (including 23 with Behçet's disease) to treat severe oral or genital ulceration (OGU)." | 3.69 | Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. ( Gardner-Medwin, JM; Powell, RJ; Smith, NJ, 1994) |
| "In a series of 12 patients suffering from an HIV infection, including 9 with confirmed AIDS, who complained about pharyngeal pain in a fixed site, having a progressive intensity and not relieved by antalgics and the specific treatments that were prescribed empirically, and for whom etiological investigation yielded negative results, Thalidomide proved to be the only effective means of healing the exulcerated, nail-mark lesions or the ulcerated, budding, neoplastic-like lesions, and of completely suppressing pain." | 3.68 | [Mouth and pharyngeal hyperalgesic syndromes in AIDS]. ( Barry, B; Depondt, J; Gehanno, P; Gorin, I; Guedon, C; Leport, C; Poignonec, S, 1990) |
| "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects." | 1.33 | Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 24 (63.16) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Iizuka, Y | 1 |
| Takase-Minegishi, K | 1 |
| Hirahara, L | 1 |
| Kirino, Y | 1 |
| Soejima, Y | 1 |
| Namkoong, HO | 1 |
| Horita, N | 1 |
| Yoshimi, R | 1 |
| Takeuchi, M | 1 |
| Takeno, M | 1 |
| Mizuki, N | 1 |
| Nakajima, H | 1 |
| Hinojosa-Azaola, A | 1 |
| Ramírez-Mulhern, I | 1 |
| Figueroa-Pariente, A | 1 |
| Martín-Nares, E | 1 |
| Dauby, N | 1 |
| Coussement, J | 1 |
| Karakike, E | 1 |
| Ungureanu, C | 1 |
| De Wit, S | 1 |
| Payen, MC | 1 |
| Kolivras, A | 1 |
| De Maubeuge, J | 1 |
| André, J | 1 |
| Song, M | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Fleming, FJ | 1 |
| Vytopil, M | 1 |
| Chaitow, J | 1 |
| Jones, HR | 1 |
| Darras, BT | 1 |
| Ryan, MM | 1 |
| Atiq, M | 1 |
| Neff, GW | 1 |
| Argyropoulos, C | 1 |
| Schroer, M | 1 |
| Kemmer, N | 1 |
| Weber, F | 1 |
| Buell, J | 1 |
| Strauss, RM | 1 |
| Bäte, J | 1 |
| Nischal, KK | 1 |
| Clayton, T | 1 |
| Gooi, J | 1 |
| Darling, JC | 1 |
| Newton-Bishop, JA | 1 |
| Verrou, E | 1 |
| Kartsios, C | 1 |
| Banti, A | 1 |
| Mihou, D | 1 |
| Kaloutsi, V | 1 |
| Lazaridou, A | 1 |
| Zervas, K | 1 |
| Jenkins, JS | 1 |
| Powell, RJ | 4 |
| Allen, BR | 2 |
| Littlewood, SM | 1 |
| Maurice, PD | 2 |
| Smith, NJ | 3 |
| Bowers, PW | 1 |
| Thompson, C | 1 |
| Sire, S | 1 |
| Fraisse, P | 1 |
| Rey, D | 1 |
| Jacquemin, C | 1 |
| Kempf, G | 1 |
| Partisani, M | 1 |
| Lang, JM | 1 |
| Naum, SM | 1 |
| Molloy, PJ | 1 |
| Kania, RJ | 1 |
| McGarr, J | 1 |
| Van Thiel, DH | 1 |
| Gardner-Medwin, JM | 1 |
| D'Arcy, PF | 1 |
| Griffin, JP | 1 |
| Verberkmoes, A | 1 |
| Boer, K | 1 |
| Wertheim, PM | 1 |
| Bronkhorst, CM | 1 |
| Lange, JM | 1 |
| Couderc, LJ | 1 |
| Balloul, E | 1 |
| Caubarrere, I | 1 |
| Domingo, P | 1 |
| Ris, J | 1 |
| López-Contreras, J | 1 |
| DeVincenzo, JP | 1 |
| Burchet, SK | 1 |
| Louvel, D | 1 |
| Musso, S | 1 |
| Métivier, S | 1 |
| Croizet, O | 1 |
| Rouquet, RM | 1 |
| Massip, P | 1 |
| Escourrou, J | 1 |
| Frexinos, J | 1 |
| Bellomo, A | 1 |
| Schorr-Lesnick, B | 1 |
| Alexander, LN | 1 |
| Wilcox, CM | 1 |
| Hamuryudan, V | 1 |
| Mat, C | 1 |
| Saip, S | 1 |
| Ozyazgan, Y | 1 |
| Siva, A | 1 |
| Yurdakul, S | 1 |
| Zwingenberger, K | 1 |
| Yazici, H | 1 |
| Jibaly, RM | 1 |
| Moallem, H | 1 |
| Fikrig, SM | 1 |
| Rabinowitz, SS | 1 |
| Jacobson, JM | 1 |
| Spritzler, J | 1 |
| Fox, L | 1 |
| Fahey, JL | 1 |
| Jackson, JB | 1 |
| Chernoff, M | 1 |
| Wohl, DA | 1 |
| Wu, AW | 1 |
| Hooton, TM | 1 |
| Sha, BE | 1 |
| Shikuma, CM | 1 |
| MacPhail, LA | 1 |
| Simpson, DM | 1 |
| Trapnell, CB | 1 |
| Basgoz, N | 1 |
| de Wazières, B | 1 |
| Gil, H | 1 |
| Magy, N | 1 |
| Berthier, S | 1 |
| Vuitton, DA | 1 |
| Dupond, JL | 1 |
| Ollivier, S | 1 |
| Bonnet, J | 1 |
| Lemann, M | 1 |
| Coffin, JC | 1 |
| Modigliani, R | 1 |
| Jian, R | 1 |
| Bertheau, P | 1 |
| Flejou, JF | 1 |
| Ryan, J | 2 |
| Randall, P | 1 |
| Colman, J | 1 |
| Pedersen, J | 1 |
| Gorin, I | 2 |
| Vilette, B | 1 |
| Gehanno, P | 2 |
| Escande, JP | 1 |
| Georghiou, PR | 1 |
| Kemp, RJ | 1 |
| Barry, B | 1 |
| Depondt, J | 1 |
| Guedon, C | 1 |
| Poignonec, S | 1 |
| Leport, C | 1 |
| Bernardo, P | 1 |
| Arrizabalaga, J | 1 |
| Iribarren, JA | 1 |
| Garde, C | 1 |
| Lehner, T | 1 |
| Sullivan, FM | 1 |
| Jenkins, S | 1 |
| Littlewood, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients[NCT00001524] | Phase 2 | 110 participants | Interventional | 1996-06-30 | Completed | ||
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790] | Phase 2 | 164 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Ulcer
| Article | Year |
|---|---|
Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Topics: Arthritis; Behcet Syndrome; Genitalia; Humans; Oral Ulcer; Skin Ulcer; Thalidomide; Ulcer | 2022 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
Thalidomide revisited.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Animals; Behcet Syndrome; Bone Marr | 1994 |
8 trials available for thalidomide and Ulcer
| Article | Year |
|---|---|
Thalidomide in severe orogenital ulceration.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Genital Diseases, Fe | 1984 |
Thalidomide effective for AIDS-related oral ulcers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Esophageal Diseases; Humans; Placebos; Sto | 1995 |
A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers.
Topics: Adult; Anti-Ulcer Agents; Esophageal Diseases; Follow-Up Studies; HIV Infections; Humans; Prospectiv | 1997 |
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Behcet Syndrome; Double-Blind Method; Drug Administration Schedule; Follow-Up Stu | 1998 |
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Double-Blind Method; Esophageal Diseases; E | 1999 |
[Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients].
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Genital Disea | 1999 |
Thalidomide effective in treating AIDS-related mouth ulcers.
Topics: Adult; AIDS-Related Opportunistic Infections; Esophageal Diseases; Female; Humans; Immunosuppressive | 1996 |
Thalidomide effective treatment for AIDS-related mouth ulcers.
Topics: Esophagus; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide; Ulcer | 1995 |
27 other studies available for thalidomide and Ulcer
| Article | Year |
|---|---|
Clinical Characteristics and Outcomes of Mexican Patients With Behçet's Syndrome.
Topics: Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Male; Mexico; Thalidomide; Ulcer | 2023 |
Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Coronary Angiography; Humans; Immune Reconstitution Infla | 2015 |
Thalidomide in refractory vulvar ulcerations associated with Crohn's disease.
Topics: Adult; Crohn Disease; Female; Humans; Immunosuppressive Agents; Thalidomide; Treatment Outcome; Ulce | 2003 |
Thalidomide neuropathy in childhood.
Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy | 2005 |
Successful treatment with thalidomide in a liver transplant recipient with giant esophageal ulcers.
Topics: Aged; Esophageal Diseases; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Thalidomid | 2006 |
A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide.
Topics: Adolescent; Conjunctival Diseases; Epidermolysis Bullosa; Female; Humans; Immunosuppressive Agents; | 2006 |
IgG multiple myeloma presented with ulcerative pyoderma gangrenosum.
Topics: Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyoderma Gangrenosum; Thalidomide; Ulcer | 2007 |
Effect of thalidomide on orogenital ulceration.
Topics: Adult; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Recurrence; Stomatiti | 1983 |
[Efficacy of thalidomide in the treatment of esophageal ulcers in human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Fatal Outcome; HIV Infections; HIV S | 1995 |
Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Female; HIV Seropositivity; HIV-1; H | 1995 |
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.
Topics: Adolescent; Adult; Behcet Syndrome; Chronic Disease; Female; Genital Diseases, Female; Genital Disea | 1994 |
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.
Topics: Adolescent; Adult; Behcet Syndrome; Chronic Disease; Female; Genital Diseases, Female; Genital Disea | 1994 |
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.
Topics: Adolescent; Adult; Behcet Syndrome; Chronic Disease; Female; Genital Diseases, Female; Genital Disea | 1994 |
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.
Topics: Adolescent; Adult; Behcet Syndrome; Chronic Disease; Female; Genital Diseases, Female; Genital Disea | 1994 |
Thalidomide for genital ulcer in HIV-positive woman.
Topics: Adult; Female; Herpes Genitalis; HIV Seropositivity; HIV-1; Humans; Thalidomide; Ulcer; Vulvar Disea | 1996 |
Esophageal ulcers in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Esophageal Diseases; Humans; Thalidomide; Ulc | 1996 |
Esophageal ulcers in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Esophageal Diseases; Humans; Thalidomide; Ulc | 1996 |
Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Child, Preschool; Esophageal Diseases; | 1996 |
Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: efficacy of thalidomide treatment.
Topics: Adult; Anti-Ulcer Agents; Esophageal Diseases; HIV Infections; Humans; Male; Thalidomide; Ulcer | 1996 |
Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV.
Topics: Acquired Immunodeficiency Syndrome; Adult; Endoscopy, Digestive System; Esophageal Diseases; Humans; | 1996 |
Steroid-resistant idiopathic esophageal ulcer in a child with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis; Child, Preschool; Drug Resistance; Esophageal Disea | 1998 |
Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment.
Topics: Esophageal Diseases; Humans; Immunocompetence; Immunosuppressive Agents; Male; Middle Aged; Thalidom | 1999 |
Thalidomide treatment of oesophageal ulceration.
Topics: Esophageal Diseases; Humans; Immunosuppressive Agents; Thalidomide; Ulcer | 2000 |
Thalidomide to treat esophageal ulcer in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Humans; Male; Thalidomide; Ulcer | 1992 |
Thalidomide in hyperalgic pharyngeal ulceration of AIDS.
Topics: Acquired Immunodeficiency Syndrome; HIV Seropositivity; Homosexuality; Humans; Male; Middle Aged; Ph | 1990 |
HIV-associated oesophageal ulcers treated with thalidomide.
Topics: Esophageal Diseases; HIV Infections; Humans; Male; Middle Aged; Thalidomide; Ulcer | 1990 |
[Mouth and pharyngeal hyperalgesic syndromes in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Middle Aged; Mouth Diseases; Pain; | 1990 |
[Effectiveness of thalidomide in non specific esophageal ulcer in patients with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Humans; Male; Thalidomide; Ulcer | 1990 |
Thalidomide, orogenital ulcers, and the risk of teratogenesis.
Topics: Abnormalities, Drug-Induced; Female; Genital Diseases, Female; Humans; Mouth Diseases; Risk; Thalido | 1985 |
Thalidomide, orogenital ulcers, and risk of teratogenicity.
Topics: Abnormalities, Drug-Induced; Female; Genital Diseases, Female; Humans; Pregnancy; Risk; Stomatitis, | 1985 |